UCB SA (UCBJF)

OTCMKTS · Delayed Price · Currency is USD
326.39
+13.55 (4.33%)
At close: Apr 8, 2026
Market Cap60.53B +78.9%
Revenue (ttm)9.09B +25.8%
Net Income1.83B +46.3%
EPS9.43 +46.5%
Shares Outn/a
PE Ratio33.09
Forward PE25.17
Dividend1.58 (0.48%)
Ex-Dividend DateApr 25, 2025
Volume159
Average Volume1,025
Open326.39
Previous Close312.84
Day's Range326.39 - 326.39
52-Week Range150.70 - 345.39
Beta0.23
RSI57.62
Earnings DateJul 30, 2026

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1925
Employees 9,765
Stock Exchange OTCMKTS
Ticker Symbol UCBJF

Financial Performance

In 2025, UCB SA's revenue was 7.74 billion, an increase of 25.83% compared to the previous year's 6.15 billion. Earnings were 1.56 billion, an increase of 46.29%.

Financial numbers in EUR Financial Statements

News

United Community Banks Inc (UCB) Stock Up 4.1% but GF Value Says Overvalued -- GF Score: 71/100

United Community Banks Inc (UCB) Stock Up 4.1% but GF Value Says Overvalued -- GF Score: 71/100

14 hours ago - GuruFocus

United Community Banks Inc (UCB) Shares Up 3.17% on Apr 9

United Community Banks Inc (UCB) Shares Up 3.17% on Apr 9

20 hours ago - GuruFocus

UCB Gets Upgraded to 'Outperform' by Keefe, Bruyette & Woods | UCB Stock News

UCB Gets Upgraded to 'Outperform' by Keefe, Bruyette & Woods | UCB Stock News

1 day ago - GuruFocus

UCB SA Reports Long-Term Bimzelx Data In Hidradenitis Suppurativa

(RTTNews) - UCB S.A. (UCBJY) announced on Friday that it has presented new post hoc data regarding Bimzelx (bimekizumab) at the American Academy of Dermatology Annual Meeting 2026 held in Denver, whic...

13 days ago - Nasdaq

Ex-Div Reminder for United Community Banks (UCB)

Looking at the universe of stocks we cover at Dividend Channel, on 3/13/26, United Community Banks Inc (Symbol: UCB) will trade ex-dividend, for its quarterly dividend of $0.25, payable on 4/3/26. As ...

4 weeks ago - Nasdaq

UCB's Bimzelx Outperforms AbbVie's Skyrizi in Psoriatic Arthritis Trial

UCB's Bimzelx Outperforms AbbVie's Skyrizi in Psoriatic Arthritis Trial

4 weeks ago - GuruFocus

Belgium's UCB in autoimmune drug deal with Antengene

Belgian drugmaker UCB has entered into an agreement to licence Antengene's experimental autoimmune ​disease therapy ATG-201 and associated ‌technology, paying $60 million up front and over $1.1 billio...

5 weeks ago - Reuters

U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

Approved indication: KYGEVVI® (doxecitine and doxribtimine) powder for oral solution (2g/2g) is approved for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with...

5 months ago - PRNewsWire